Mechanism of action
It is a selective, oral, second-generation Bruton’s tyrosine kinase (BTK) inhibitor. The mechanism of action of acalabrutinib is the inhibition of BTK, an enzyme involved in the B-cell activation signaling pathway, leading to decreased proliferation and survival of B-cells
Spectrum
The spectrum of activity of acalabrutinib is primarily in hematologic malignancies, such as mantle cell lymphoma and chronic lymphocytic leukemia (CLL). It has also shown efficacy in other B-cell lymphomas
